In this phase Ib clinical trial, we demonstrate for the first time the feasibility of concurrent inhibition of PKC and MEK in patients with advanced uveal melanoma; however, limited clinical activity was observed in this challenging patient population. The gene discussed is MAP2K7; the disease is uveal melanoma.